Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Cardiac disorders – page 2

  • 481 clinical trials
  • 225 recruiting
  • 172 conditions
  • 28 countries

Conditions in this area

172 conditions with trials, the busiest first

Atrial fibrillation55Cardiac failure42Coronary artery disease37Acute myocardial infarction30Cardiac amyloidosis29Acute coronary syndrome21Cardiac arrest19Cardiac failure chronic17Cardiovascular disorder16Heart failure with reduced ejection fraction16Hypertrophic cardiomyopathy16Cardiac failure acute14Glycogen storage disease type II14Heart failure with preserved ejection fraction13Myocardial infarction13Cardiomyopathy11Myocardial ischaemia11Cardiogenic shock10Chronic coronary syndrome10Dilated cardiomyopathy9Myocarditis9Aortic valve stenosis7Chronic kidney disease6Trisomy 216+148

Clinical trials in Cardiac disorders

481 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

481 clinical trials

Coronary artery disease

Recruiting

Study on Coronary Artery Disease: Evaluating Myocardial Blood Flow Using SYN2, Regadenoson, and Adenosine in Patients with Heart Conditions

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Adenosine
  • Sponsor:Synektik S.A.

Atrial fibrillation

Recruiting

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:BulgariaBulgaria
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Cardiac amyloidosis

Recruiting

Long‑Term Study of Acoramidis on Heart Function and Amyloid Burden in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR‑CM)

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis
  • Sponsor:Eidos Therapeutics Inc.

Atrial fibrillation

Recruiting

Efficacy and Safety of BAY 3670549 in Adults with Atrial Fibrillation: A Randomized, Double‑Blind, Placebo‑Controlled Phase 2 Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Bayer AG

Atrial fibrillation

Recruiting

Phase 3 Study of Etripamil Nasal Spray Compared with Placebo in Patients with Atrial Fibrillation and Rapid Ventricular Rate

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Etripamil
  • Sponsor:Milestone Pharmaceuticals Inc.

Heart failure with preserved ejection fraction

Recruiting

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azd5004
  • Sponsor:AstraZeneca AB

Myocardial ischaemia

Recruiting

Ticagrelor, Acetylsalicylic Acid and Prasugrel in Patients with Acute Coronary Syndrome: A Study of Antiplatelet Management

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz

Arteriosclerosis coronary artery+2

Recruiting

Triple vs dual therapy with rosuvastatin, ezetimibe and bempedoic acid in patients with atherosclerotic heart disease and high cholesterol undergoing revascularisation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bempedoic Acid
  • Sponsor:Medical University Of Graz

Myocardial ischaemia+1

Recruiting

Discontinuing Acetylsalicylic Acid vs Continued Use in Patients ≥ 65 Years with Stable Chronic Coronary Syndrome

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Odense University Hospital

Atrial fibrillation+1

Recruiting

Safety of flecainide acetate compared with amiodarone hydrochloride and sotalol in patients with atrial fibrillation and stable coronary artery disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Flecainide Acetate
  • Sponsor:UZ Leuven

Arteriosclerosis coronary artery

Recruiting

Bempedoic acid in drug combination for patients with coronary artery disease without prior cardiovascular events

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Daiichi Sankyo Europe GmbH

Cardiac amyloidosis

Recruiting

Evaluation of [68Ga]Ga-FAPI-46 PET Imaging for Staging and Detecting Disease Progression in Patients with Transthyretin Cardiac Amyloidosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Substances studied in this area

The therapies tested most often in Cardiac disorders trials.

Acetylsalicylic Acid44 clinical trialsClopidogrel30 clinical trialsTicagrelor27 clinical trialsSodium Chloride25 clinical trialsDapagliflozin22 clinical trialsApixaban21 clinical trialsEmpagliflozin20 clinical trialsRivaroxaban19 clinical trialsPrasugrel18 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.